J Craniofac Surg:颌下经导管灌注麻醉在颌下腺手术中的疗效和安全性

2020-08-08 MedSci原创 MedSci原创

本研究旨在评价颌下腺手术中联合使用舌神经阻滞和皮下浸润进行麻醉的可行性、安全性和效果。

本研究旨在评价颌下腺手术中联合使用舌神经阻滞和皮下浸润进行麻醉的可行性、安全性和效果。

将38例经颌下腺手术切除的良性肿瘤患者随机分为2组:A组患者通过导管灌注、舌神经阻滞、皮下浸润麻醉等方式进行颌下腺麻醉;B组患者仅采用舌神经阻滞和皮下浸润麻醉。下颌下腺手术在麻醉给药后5分钟内进行,术后分别在术前、皮肤切开过程中(T1)、下颌下腺牵拉过程中(T2)、下颌下腺摘除过程中(T3)、术后2、6、12、24小时进行数值评分表(NRS)评价。术后还测定了镇痛药物的用量。

结果显示,手术前、手术后T1、6、12、24小时的NRS无明显差异(P>0.01),而A组患者在手术后T2、T3、2小时观察到的NRS与B组要低很多(P<0.01)。

该研究结果表明,在颌下腺手术过程中,联合应用颌下经导管灌注与舌神经阻滞和皮下浸润可作为一种有效的麻醉方法。

原始出处:

Ruohuang LuZhiqiang Xiao, et al., The Efficacy and Safety of Submandibular Transcatheter Perfusion Anesthesia in Submandibular Gland Surgery. J Craniofac Surg. Mar/Apr 2020;31(2):e199-e202. doi: 10.1097/SCS.0000000000006140.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
    2020-08-10 lsj631
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
    2020-08-08 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Mar 05 21:49:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716599, encodeId=b3421e1659936, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Sun Feb 21 01:49:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956807, encodeId=aac7195680edd, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Sun Aug 09 18:49:44 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510317, encodeId=a274151031e8e, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Mon Aug 10 09:49:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032609, encodeId=04c51032609aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Aug 08 21:49:44 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806997, encodeId=f17780699e11, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d9b2431390, createdName=123b8894m52暂无昵称, createdTime=Sat Aug 08 20:34:52 CST 2020, time=2020-08-08, status=1, ipAttribution=)]
    2020-08-08 123b8894m52暂无昵称

    学习

    0

相关资讯

右美托咪定麻醉期间,小心患者出现呼吸暂停

右美托咪定在临床上应用广泛,虽然其药理学特性对呼吸的影响轻微,很少出现严重的呼吸抑制甚至暂停,但同样不能小觑。

术前评估决策老年患者麻醉方法1例

患者,女,80岁,身高154 cm,体质量85kg,体质量指数(BMI)35.8kg/m2,肥胖。患者无烟酒嗜好,上下颌均有活动义齿

JACC:经导管主动脉瓣置换术使用清醒镇静与全身麻醉的比较

尽管不同医院间的差异很大,但使用CS进行TAVR的比例继续升高。与GA相比,尽管获益的幅度似乎小于既往研究,但将CS用于TAVR可以改善结局

麻醉诱导期与麻醉监护密切相关的突发事件3例分析

临床麻醉是最具风险的医学领域之一。麻醉期间未及时全面地监测患者是引发围术期麻醉并发症的主要原因之一。世界麻醉医师学会联合会(WFSA)1992年发布了“临床麻醉安全国际标准”,

J Invest Surg:预用阿托品可以抑制麻醉期间芬太尼引起的咳嗽

芬太尼和阿托品分别是用于麻醉诱导期间镇痛和预处理的药物。本研究旨在观察用于预处理的阿托品对麻醉诱导期间使用芬太尼时出现咳嗽的影响。

BMC Anesthesiol:小剂量瑞芬太尼预处理可抑制舒芬太尼诱导的全麻诱导期咳嗽

静脉使用舒芬太尼可引起咳嗽。本研究旨在评估在全麻诱导过程中,预先注射商场剂量的瑞芬太尼对舒芬太尼引起的咳嗽的抑制作用。